Haoxi Health Technology Ltd Announces $4 Million Registered Direct Offering

Rhea-AI Summary

Haoxi Health Technology (NASDAQ: HAO) entered a definitive agreement with certain investors for a registered direct offering of 10,000,000 Class A ordinary shares (or pre-funded warrants) at $0.40 per share, with pre-funded warrants carrying a $0.33 exercise price. Expected gross proceeds are about $4 million, with closing targeted on or about July 13, 2026 subject to customary conditions. Univest Securities is the sole placement agent. The offering is made under Haoxi’s effective Form F-3 shelf registration that became effective on June 13, 2025.

Positive

• $4 million expected gross proceeds to strengthen cash position
• Fixed offering price of $0.40 per share provides valuation clarity
• Use of effective Form F-3 shelf enables relatively quick capital access

Negative

• Issuance of 10,000,000 new shares or pre-funded warrants implies shareholder dilution
• Offering price of $0.40 may be below prior trading levels, potentially pressuring valuation

News Market Reaction – HAO

-66.48% 133.9x vol

328 alerts

-66.48% Session close to close

+88.4% Peak Tracked

-74.5% Trough Tracked

$2.33M Market Cap

133.9x Rel. Volume

In the Jul 10 session, HAO declined 66.48%, reflecting a significant negative market reaction. Argus tracked a peak move of +88.4% during that session. Argus tracked a trough of -74.5% from its starting point during tracking. Our momentum scanner triggered 328 alerts that day, indicating exceptionally high trading interest and price volatility. Trading volume was exceptionally heavy at 133.9x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -66.5% in the session following this news. A sharp decline would be consistent wit...

Analysis

The stock dropped -66.5% in the session following this news. A sharp decline would be consistent with Haoxi’s past offerings, where three similar financings averaged roughly -61.47% next-day moves. Investors may again be focusing on dilution risk, with limited offset from relatively low reported short interest.

Key Figures

Class A shares offered: 10,000,000 shares Share purchase price: $0.40 per share Pre-funded warrant exercise price: $0.33 per share +5 more

8 metrics

Class A shares offered 10,000,000 shares Registered direct offering

Share purchase price $0.40 per share Registered direct offering

Pre-funded warrant exercise price $0.33 per share Pre-funded warrants in offering

Gross proceeds $4 million Aggregate gross proceeds from offering

Par value per share $0.32 per share Class A Ordinary Shares

Expected closing date July 13, 2026 Registered direct offering closing

Form type Form F-3 (File No. 333-287686) Shelf registration statement

Shelf effectiveness date June 13, 2025 Form F-3 became effective

Previous Offering Reports

3 past events · Latest: May 11 (Negative)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	Registered direct offering	Negative	-93.8%	Company agreed to $6.5M registered direct offering at $0.25 per share.
Sep 20	Follow-on offering closing	Negative	-17.2%	Closed $12M underwritten follow-on offering of 4M units with warrants.
Sep 19	Follow-on offering pricing	Negative	-73.3%	Announced pricing of $12M underwritten follow-on units at $3.00 each.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past equity offerings for Haoxi have consistently been followed by sharp one-day share price declines.

Key Terms

registered direct offering, pre-funded warrants, shelf registration statement, form f-3, +1 more

5 terms

registered direct offering financial

"at a purchase price of $0.40 per share in a registered direct offering."

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"or pre-funded warrants in lieu thereof) at a purchase price of $0.40"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"The registered direct offering is being made pursuant to a shelf registration statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form f-3 regulatory

"shelf registration statement on Form F-3 (File No. 333-287686) previously filed"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectus supplement regulatory

"A final prospectus supplement and accompanying prospectus describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEIJING, July 10, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Ltd (NASDAQ: HAO) (“Haoxi” or the “Company”), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 10,000,000 of the Company’s Class A Ordinary Shares, par value $0.32 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.40 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share.

The aggregate gross proceeds to the Company of this offering are expected to be approximately $4 million. The transaction is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions.

Univest Securities, LLC is acting as the sole placement agent.

The registered direct offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-287686) previously filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) and became effective by on June 13, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus will be filed by the Company and, upon filing, can be obtained at the SEC's website at www.sec.gov.

About Haoxi Health Technology Ltd

Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.

Haoxi Health Technology Ltd

Investor Relations

ir@haoximedia.com

FAQ

What is Haoxi Health Technology (NASDAQ: HAO) raising in its July 2026 offering?

Haoxi Health Technology plans to raise approximately $4 million in gross proceeds. According to Haoxi, this will come from selling 10,000,000 Class A ordinary shares, or pre-funded warrants in lieu, at a purchase price of $0.40 per share in a registered direct offering.

What are the key terms of Haoxi Health Technology’s $4 million registered direct offering (HAO)?

The offering covers 10,000,000 Class A ordinary shares at $0.40 per share, or pre-funded warrants at the same price less a $0.33 exercise price. According to Haoxi, gross proceeds are expected to be about $4 million, before expenses.

When is the closing date for Haoxi Health Technology’s registered direct offering?

The transaction is expected to close on or about July 13, 2026. According to Haoxi, the closing remains subject to the satisfaction of customary closing conditions that typically apply to similar registered direct offerings under U.S. securities laws.

How will pre-funded warrants work in Haoxi Health Technology’s (HAO) July 2026 offering?

Investors may receive pre-funded warrants instead of shares, priced at $0.40 minus a $0.33 exercise price. According to Haoxi, the economic purchase price matches the shares, with the remaining amount payable upon exercise of the pre-funded warrants into Class A ordinary shares.

Under which SEC registration is Haoxi Health Technology’s $4 million offering being conducted?

The offering uses Haoxi’s shelf registration statement on Form F-3 (File No. 333-287686). According to Haoxi, this registration became effective on June 13, 2025, allowing the company to conduct this registered direct offering with a prospectus supplement filed with the SEC.

Who is the placement agent for Haoxi Health Technology’s July 2026 registered direct offering?

Univest Securities is acting as the sole placement agent for the transaction. According to Haoxi, investors can obtain electronic copies of the final prospectus supplement and accompanying prospectus from Univest Securities once available, or directly from the SEC’s official website.